ANALYSIS OF UNFAVORABLE PROGNOSTIC FACTORS IN PATIENTS WHO RECEIVED HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL HEMOPOIETIC STEM CELLS TRANSPLANTATION FOR RELAPSES AND RESISTANT FORMS OF HODGKIN''S LYMPHOMA
PDF (Русский)

Keywords

HODGKIN'S LYMPHOMA
HIGH DOSE CHEMOTHERAPY
AUTOLOGOUS STEM CELL TRANSPLANTATION

How to Cite

Alekseev, S., Subora, A., Shilo, P., Ishmatova, I., Semiglazova, T., Filatova, L., Kuleva, S., Oleynik, Y., Chudinovskikh, Y., Kharchenko, Y., Motalkina, M., Zyuzgin, I., & Shalaev, S. (2018). ANALYSIS OF UNFAVORABLE PROGNOSTIC FACTORS IN PATIENTS WHO RECEIVED HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL HEMOPOIETIC STEM CELLS TRANSPLANTATION FOR RELAPSES AND RESISTANT FORMS OF HODGKIN’’S LYMPHOMA. Voprosy Onkologii, 64(3), 414–418. https://doi.org/10.37469/0507-3758-2018-64-3-414-418

Abstract

High dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) is suggested as the standard of treatment of patients with relapsed or refractory Hodgkin’s lymphoma (HL) providing long-term disease-free survival in over 50 % of patients. The insufficient number of Russian medical centers, which can provide HDCT with ASCT, result into a broken chain of treatment. The main goal of this thesis is the evaluation of a timely mannered qualified medical help as potential independent prognosis factor. Our study included data of patients with refractory or relapsed HL who underwent treatment between 2013 and 2017 in our Center. Due to our data the negative prognostic factors affecting progression-free survival are: primary refractory disease (60 % vs 94 %; HR 2,1 [95 % CI 1.20-3.56], p=0.041); response for the 1st line of salvage therapy less than complete remission (CR) (35 % vs 91 %; HR 2,4 [95 % CI 1.81-3.24], p=0.022), presence of chain treatment disruption (41 % vs 90 %; HR 2,9 [95 % CI 2.43-4.2], p=0.029), disease status less than CR prior ASCT (29 % vs 87 %; HR 4,3 [95 % CI 2.9-6.1], p=0.009). Our results demonstrate that timely mannered qualified medical care is a key component that improves the survival of patients with relapses and refractory forms of Hodgkin’s lymphoma.
https://doi.org/10.37469/0507-3758-2018-64-3-414-418
PDF (Русский)

References

Moccia A.A., Donaldson J., Chhanabhai M. et al. International prognostic score in advancedstage Hodgkin's lymphoma: altered utility in the modern era // J. Clin. Oncol. - 2012. - Vol. 30. - P. 3383-3388.

Meyer R.M., Hoppe R.T. Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy // Hematology Am. Soc. Hematol. Educ. Program. - 2012. - Vol. 2012. - P 313-321.

Kuruvilla J. Standard therapy of advanced Hodgkin lymphoma // Hematology Am. Soc. Hematol. Educ. Program. - 2009. - Vol. 2009. - P. 497-506.

Smith S.D., Moskowitz C.H., Dean R. et al. Autologous stem cell transplant for relapsed/refractory Hodgkin lymphoma: results from two transplant centres // Br. J. Haematol. - 2011. - Vol. 153. - P. 358-363.

Majhail N.S., Weisdorf D.J., Defor TE. et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma // Biol. Blood Marrow Tranwsplant. - 2006. - Vol. 12. - P. 1065-1072.

Sorohi B., Cunningham D., Powles R. et al. Longterm outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma // Ann. Oncol. - 2008. - Vol. 19. - P. 312-319.

Schmitz N., Pfstner B., Sextro M. et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantationfor relapsed chemosensitive Hodgkin's disease: a randomized trial // Lancet. - 2002. - Vol. 359. - P. 2065-2071.

Rancea M., Monsef I., von Tresckov B. et al. Highdose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma // Cochrane Database Syst. Rev. - 2013. - Vol. 6. - CD009411.

Cheson B.D., Horning S.J., Coiffier B. et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group // J. Clin. Oncol. - 1999. - Vol. 17(4). - P. 1244.

Josting A., Raemakers J.M., Diehl V. et al. New concepts for relapsed Hodgkin>s disease // Ann. Oncol. - 2002. - Vol. 13. - suppl 1. - P. 117-121.

Pavone V., Gaudio F., Console G. et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation // Bone Marrow Transplant. - 2006. - Vol. 37. - P. 719-724.

Моталкина М.С., Кулева С.А., Алексеев С.М. и др. Современные способы улучшения мобилизации стволовых кроветворных клеток: обзор литературы // Medline.ru. - 2015. - Т 16. - С. 916-933.

Sharma A., Kayal S., Iqbal S. et al. Comparison of BEAM vs LEAM regimen in autologous transplant for lymphoma at AIIMS. - Springerplus, 2013. - Vol. 2. - P. 489.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

© АННМО «Вопросы онкологии», Copyright (c) 2018